Free Trial

Bicycle Therapeutics (BCYC) Competitors

Bicycle Therapeutics logo
$7.81 -0.07 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$7.61 -0.20 (-2.56%)
As of 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCYC vs. IDYA, DNLI, BHC, TVTX, ETNB, SRPT, OCUL, DYN, ANIP, and VERA

Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include IDEAYA Biosciences (IDYA), Denali Therapeutics (DNLI), Bausch Health Cos (BHC), Travere Therapeutics (TVTX), 89BIO (ETNB), Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

Bicycle Therapeutics vs. Its Competitors

Bicycle Therapeutics (NASDAQ:BCYC) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

IDEAYA Biosciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -1,257.00%. IDEAYA Biosciences' return on equity of -31.42% beat Bicycle Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics-1,257.00% -32.43% -26.80%
IDEAYA Biosciences N/A -31.42%-29.45%

Bicycle Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bicycle Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$35.28M15.34-$169.03M-$3.51-2.23
IDEAYA Biosciences$7M355.82-$274.48M-$3.79-7.50

In the previous week, IDEAYA Biosciences had 19 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 21 mentions for IDEAYA Biosciences and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.55 beat IDEAYA Biosciences' score of 0.42 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEAYA Biosciences
6 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bicycle Therapeutics presently has a consensus price target of $22.22, suggesting a potential upside of 184.54%. IDEAYA Biosciences has a consensus price target of $44.50, suggesting a potential upside of 56.58%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
1 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50
IDEAYA Biosciences
1 Sell rating(s)
3 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.74

Summary

Bicycle Therapeutics beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

Get Bicycle Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCYC vs. The Competition

MetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$546.14M$3.44B$6.19B$10.60B
Dividend YieldN/A2.26%5.72%4.86%
P/E Ratio-2.2323.2429.6428.46
Price / Sales15.34477.59577.46128.87
Price / CashN/A44.5736.5560.64
Price / Book0.6810.3512.076.53
Net Income-$169.03M-$52.53M$3.32B$276.75M
7 Day Performance-9.71%-0.22%-0.16%0.20%
1 Month Performance10.16%10.89%5.76%1.67%
1 Year Performance-69.15%14.19%65.71%32.73%

Bicycle Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCYC
Bicycle Therapeutics
3.4867 of 5 stars
$7.81
-0.9%
$22.22
+184.5%
-69.9%$546.14M$35.28M-2.23240Upcoming Earnings
IDYA
IDEAYA Biosciences
4.2953 of 5 stars
$26.77
+2.0%
$43.36
+62.0%
-5.2%$2.30B$7M-7.0680News Coverage
Analyst Forecast
Analyst Revision
DNLI
Denali Therapeutics
4.137 of 5 stars
$14.98
-2.5%
$33.50
+123.6%
-39.3%$2.25B$330.53M-5.35430
BHC
Bausch Health Cos
4.7105 of 5 stars
$6.15
+1.6%
$9.00
+46.5%
-23.0%$2.24B$9.63B23.6420,700News Coverage
Positive News
Upcoming Earnings
TVTX
Travere Therapeutics
2.9624 of 5 stars
$26.20
+4.1%
$35.21
+34.4%
+52.9%$2.24B$233.18M-12.84460News Coverage
Upcoming Earnings
ETNB
89BIO
2.8707 of 5 stars
$14.80
flat
$25.81
+74.4%
+82.3%$2.19BN/A-4.1040Analyst Downgrade
Short Interest ↓
SRPT
Sarepta Therapeutics
4.6 of 5 stars
$21.96
-0.7%
$34.42
+56.7%
-82.5%$2.16B$1.90B-25.241,372Analyst Forecast
OCUL
Ocular Therapeutix
4.289 of 5 stars
$11.85
+0.6%
$22.63
+90.9%
+0.4%$2.05B$63.72M-9.26230Analyst Revision
DYN
Dyne Therapeutics
3.0182 of 5 stars
$14.03
-0.1%
$34.07
+142.8%
-51.0%$2.00BN/A-3.63100Positive News
ANIP
ANI Pharmaceuticals
4.1315 of 5 stars
$88.61
-1.3%
$99.14
+11.9%
+56.1%$1.95B$614.38M-115.08600
VERA
Vera Therapeutics
2.8976 of 5 stars
$30.49
+1.3%
$63.00
+106.6%
-26.5%$1.92BN/A-8.5240News Coverage

Related Companies and Tools


This page (NASDAQ:BCYC) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners